AnalystBook Research · Company Intelligence

Advanced Flower Capital Inc.

AFCGNasdaq

Built from Advanced Flower Capital Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Advanced Flower Capital's revenue fell 46.2% and net income turned negative, even as insiders bought $6.6M of stock.

The read at a glance✓ Audited against SEC data
  • Business mix — Cannabis-focused secured lenderNote
  • Revenue — Revenue fell 46.2% to $24.6MWatch
  • Profitability — Net loss was $20.7MWatch
  • Cash quality — Cash from ops fell to $11.2MWatch
  • Balance sheet — Equity fell 12.8% to $175.6MWatch
  • Insiders — 35 buys / 0 sells; $6.6M boughtOK
  • Accounting — No forensic screen in bundleNote

Business

Advanced Flower Capital is an externally managed institutional lender focused on senior secured loans, mortgage loans, and debt securities, with a specialization in state-law-compliant cannabis companies.

Leadership changes

From Advanced Flower Capital Inc.'s own filings, the day they're filed.

  • Pete Sattelmair · Directors · appointmenteff. 2026-03-16
  • Robyn Tannenbaum · Chief Investment Officer · appointmenteff. 2024-10-21
  • Leonard M. Tannenbaum · Chief Investment Officer · departureeff. 2024-10-21

Latest filings

  • 8-K · Company announcement2026-09-29
  • 8-K · Company announcement2026-09-15
  • 8-K · Company announcement2026-08-26
  • 8-K · Company announcement2026-08-13
  • 10-Q · Quarterly report2026-08-13
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Advanced Flower Capital Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.